Innate Pharma to Host Key Opinion Leader Discussion on the Potential Role of Lacutamab Across T-Cell LymphomasVirtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021
Published: Feb 03, 2021 Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate” or the “ Company”) today announced that it will host a virtual key opinion leader (KOL) discussion focused on the potential role of its lead investigational drug candidate, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas. The event will be held virtually on Tuesday, February 9, 2021 at 2:00 p.m. CET / 8:00 a.m. ET. The event will feature presentations from the Company’s executive leadership team, as well as the following KOL...